# A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

> **NCT07221669** · PHASE3 · RECRUITING · sponsor: **Biogen** · enrollment: 30 (estimated)

## Conditions studied

- Muscular Atrophy, Spinal

## Interventions

- **DRUG:** Salanersen

## Key facts

- **NCT ID:** NCT07221669
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-28
- **Primary completion:** 2028-11-28
- **Final completion:** 2032-05-29
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221669, "A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07221669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*